{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T17:43:41Z","timestamp":1788975821454,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Foundation for Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.cpcardiol.2021.100860","type":"journal-article","created":{"date-parts":[[2021,4,3]],"date-time":"2021-04-03T20:00:07Z","timestamp":1617480007000},"page":"100860","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Urocortin-2 in Acute Heart Failure: Role as a Marker of Volume Overload and Pulmonary Hypertension"],"prefix":"10.1016","volume":"47","author":[{"given":"Mariana","family":"Pintalhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Maia-Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo","family":"Castro-Chaves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Ad\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ant\u00f3nio S.","family":"Barros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Clara Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adelino","family":"Leite-Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo","family":"Bettencourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Bras-Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpcardiol.2021.100860_bib0001","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s11897-017-0351-y","article-title":"Acute heart failure: definition, classification and epidemiology","volume":"14","author":"Kurmani","year":"2017","journal-title":"Curr Heart Fail Rep"},{"key":"10.1016\/j.cpcardiol.2021.100860_bib0002","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/sj.bjp.0705985","article-title":"CRF2 receptors are highly expressed in the human cardiovascular system and their cognate ligands urocortins 2 and 3 are potent vasodilators","volume":"143","author":"Wiley","year":"2004","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.cpcardiol.2021.100860_bib0003","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.drudis.2015.02.012","article-title":"Urocortin 2 in cardiovascular health and disease","volume":"20","author":"Adao","year":"2015","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.cpcardiol.2021.100860_bib0004","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s10557-019-06895-9","article-title":"Cardiovascular effects of urocortin-2: pathophysiological mechanisms and therapeutic potential","volume":"33","author":"Monteiro-Pinto","year":"2019","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.cpcardiol.2021.100860_bib0005","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1006\/jmcc.2002.1529","article-title":"Activation of protein kinase B\/Akt by urocortin is essential for its ability to protect cardiac cells against hypoxia\/reoxygenation-induced cell death","volume":"34","author":"Brar","year":"2002","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.cpcardiol.2021.100860_bib0006","doi-asserted-by":"crossref","first-page":"8508","DOI":"10.1074\/jbc.275.12.8508","article-title":"Urocortin protects against ischemic and reperfusion injury via a MAPK-dependent pathway","volume":"275","author":"Brar","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cpcardiol.2021.100860_bib0007","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0735-1097(02)01930-7","article-title":"Urocortin promotes hemodynamic and bioenergetic recovery and improves cell survival in the isolated rat heart exposed to ischemia\/reperfusion","volume":"40","author":"Scarabelli","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2021.100860_bib0008","doi-asserted-by":"crossref","first-page":"H928","DOI":"10.1152\/ajpheart.01135.2006","article-title":"Urocortin prevents mitochondrial permeability transition in response to reperfusion injury indirectly by reducing oxidative stress","volume":"293","author":"Townsend","year":"2007","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.cpcardiol.2021.100860_bib0009","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijcard.2015.06.011","article-title":"Urocortin 2 protects heart and kidney structure and function in an ovine model of acute decompensated heart failure: Comparison with dobutamine","volume":"197","author":"Rademaker","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cpcardiol.2021.100860_bib0010","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1161\/CIRCULATIONAHA.105.561308","article-title":"Integrated hemodynamic, hormonal, and renal actions of urocortin 2 in normal and paced sheep: beneficial effects in heart failure","volume":"112","author":"Rademaker","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2021.100860_bib0011","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/FJC.0000000000000190","article-title":"Chronic urocortin 2 administration improves cardiac function and ameliorates cardiac remodeling after experimental myocardial infarction","volume":"65","author":"Ellmers","year":"2015","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.cpcardiol.2021.100860_bib0012","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1093\/eurheartj\/ehm340","article-title":"Urocortin 2 infusion in human heart failure","volume":"28","author":"Davis","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2021.100860_bib0013","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jchf.2013.07.003","article-title":"Urocortin-2 infusion in acute decompensated heart failure: findings from the UNICORN study (urocortin-2 in the treatment of acute heart failure as an adjunct over conventional therapy)","volume":"1","author":"Chan","year":"2013","journal-title":"JACC Heart failure"},{"key":"10.1016\/j.cpcardiol.2021.100860_bib0014","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1042\/CS20070364","article-title":"Urocortin 2 combined with angiotensin-converting enzyme inhibition in experimental heart failure","volume":"114","author":"Rademaker","year":"2008","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.cpcardiol.2021.100860_bib0015","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1097\/HJH.0b013e3283493776","article-title":"Urocortin 2 sustains haemodynamic and renal function during introduction of beta-blockade in experimental heart failure","volume":"29","author":"Rademaker","year":"2011","journal-title":"J Hypertens"},{"key":"10.1016\/j.cpcardiol.2021.100860_bib0016","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1161\/CIRCHEARTFAILURE.112.000205","article-title":"Interactions of enhanced urocortin 2 and mineralocorticoid receptor antagonism in experimental heart failure","volume":"6","author":"Rademaker","year":"2013","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cpcardiol.2021.100860_bib0017","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1161\/CIRCHEARTFAILURE.109.861336","article-title":"Urocortin 2 inhibits furosemide-induced activation of renin and enhances renal function and diuretic responsiveness in experimental heart failure","volume":"2","author":"Rademaker","year":"2009","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cpcardiol.2021.100860_bib0018","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/bcp.13033","article-title":"Cardiovascular effects of urocortin 2 and urocortin 3 in patients with chronic heart failure","volume":"82","author":"Stirrat","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.cpcardiol.2021.100860_bib0019","first-page":"115","article-title":"Relationship of urocortin-2 with systolic and diastolic functions and coronary artery disease: an observational study","volume":"12","author":"Topal","year":"2012","journal-title":"Anadolu Kardiyol Derg"},{"key":"10.1016\/j.cpcardiol.2021.100860_bib0020","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1084\/jem.20161924","article-title":"Corticotropin releasing hormone receptor 2 exacerbates chronic cardiac dysfunction","volume":"214","author":"Tsuda","year":"2017","journal-title":"J Exp Med"},{"key":"10.1016\/j.cpcardiol.2021.100860_bib0021","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1373\/clinchem.2015.252932","article-title":"High-sensitivity sandwich ELISA for plasma NT-proUcn2: plasma concentrations and relationship to mortality in heart failure","volume":"62","author":"Liew","year":"2016","journal-title":"Clin Chem."},{"key":"10.1016\/j.cpcardiol.2021.100860_bib0022","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/cvr\/cvy076","article-title":"Urocortin-2 improves right ventricular function and attenuates pulmonary arterial hypertension","volume":"114","author":"Adao","year":"2018","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.cpcardiol.2021.100860_bib0023","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/clpt.1993.100","article-title":"The need for a sodium retention score in clinical trials of heart failure","volume":"54","author":"Cody","year":"1993","journal-title":"Clin Pharmacol Therap"},{"key":"10.1016\/j.cpcardiol.2021.100860_bib0024","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/ehjci\/jev014","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"16","author":"Lang","year":"2015","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.cpcardiol.2021.100860_bib0025","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.echo.2010.05.010","volume":"23","author":"Rudski","year":"2010","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.cpcardiol.2021.100860_bib0026","doi-asserted-by":"crossref","unstructured":"Patil I. ggstatsplot: \u2018ggplot2\u2019 Based Plots with Statistical Details. 2018. Available at: https:\/\/CRAN.R-project.org\/package=ggstatsplot. Accessed 4th December 2020.","DOI":"10.32614\/CRAN.package.ggstatsplot"},{"key":"10.1016\/j.cpcardiol.2021.100860_bib0027","series-title":"Regression modeling strategies","author":"Harrell","year":"2015"},{"key":"10.1016\/j.cpcardiol.2021.100860_bib0028","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.abb.2018.11.021","article-title":"Natural and synthetic peptides in the cardiovascular diseases: an update on diagnostic and therapeutic potentials","volume":"662","author":"Grieco","year":"2019","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.cpcardiol.2021.100860_bib0029","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jacc.2006.09.035","article-title":"Urocortin 2 infusion in healthy humans: hemodynamic, neurohormonal, and renal responses","volume":"49","author":"Davis","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2021.100860_bib0030","first-page":"315","article-title":"Urocortin 2 in patients with hypertension treated with angiotensin converting enzyme inhibitors or angiotensin receptor blockers","volume":"70(2)","author":"Walczewska","year":"2019","journal-title":"J Physiol Pharmacol"},{"key":"10.1016\/j.cpcardiol.2021.100860_bib0031","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1093\/cvr\/cvy117","article-title":"Urocortin 2: will a drug targeting both the vasculature and the right ventricle be the future of pulmonary hypertension therapy?","volume":"114","author":"Stenmark","year":"2018","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.cpcardiol.2021.100860_bib0032","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1097\/01.hjh.0000523326.09703.2f","article-title":"[PP.05.28] Relationship between urocortin 2 concentration and metabolic profile in healthy subjects","volume":"35","author":"Siga","year":"2017","journal-title":"J Hypertens"},{"key":"10.1016\/j.cpcardiol.2021.100860_bib0033","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13293-018-0208-4","article-title":"Sexually dimorphic metabolic responses mediated by CRF(2) receptor during nutritional stress in mice","volume":"9","author":"Paruthiyil","year":"2018","journal-title":"Biol Sex Differ"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014628062100075X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014628062100075X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:57:20Z","timestamp":1758938240000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014628062100075X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S014628062100075X"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2021.100860","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Urocortin-2 in Acute Heart Failure: Role as a Marker of Volume Overload and Pulmonary Hypertension","name":"articletitle","label":"Article Title"},{"value":"Current Problems in Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2021.100860","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}],"article-number":"100860"}}